BBIO vs PH · rev $221.9M vs P/E 28, rev $19.85B
BridgeBio Pharma Inc (BBIO) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
BBIO currently screens at market cap $13.24B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the BBIO and PH stock pages for the full models.
Not investment advice.